Systemic Polyarteritis Nodosa in the Young: A Single-Center Experience Over Thirty-Two Years by Eleftheriou, D et al.
ARTHRITIS & RHEUMATISM
Vol. 65, No. 9, September 2013, pp 2476–2485
DOI 10.1002/art.38024
© 2013, American College of Rheumatology
Systemic Polyarteritis Nodosa in the Young
A Single-Center Experience Over Thirty-Two Years
Despina Eleftheriou,1 Michael J. Dillon,2 Kjell Tullus,1 Stephen D. Marks,1
Clarissa A. Pilkington,1 Derek J. Roebuck,1 Nigel J. Klein,2 and Paul A. Brogan3
Objective. Polyarteritis nodosa (PAN) is a rare
disease of childhood. The aims of this study were to
describe the clinical features, treatment, and outcome of
systemic childhood PAN and to identify predictors of
relapse.
Methods. A single-center retrospective medical
records review of children with PAN fulfilling the Euro-
pean League Against Rheumatism (EULAR)/Paediatric
Rheumatology European Society (PRES)/Paediatric
Rheumatology International Trials Organisation
(PRINTO) classification criteria who were seen over a
32-year period was performed. Data on demographic
and clinical features, treatments, relapses (recurrence
of clinical signs/symptoms or occurrence of new symp-
toms after initial remission requiring escalation or
resumption of immunosuppressive therapy), and deaths
were recorded. A disease activity score was retrospec-
tively assigned using the Paediatric Vasculitis Activity
Score (PVAS) instrument. Cox regression analysis was
used to identify significant predictors of relapse.
Results. Sixty-nine children with PAN were iden-
tified; 55% were male, and their median age was 8.5
years (range 0.9–15.8 years). Their clinical features at
presentation were fever (87%), myalgia (83%), skin
(88%), renal (19%), severe gastrointestinal (GI) (10%),
and neurologic (10%) involvement. The PVAS at presen-
tation was 9 of 63 (range 4–24). Histopathologic analy-
sis of the skin showed necrotizing vasculitis in biopsy
samples from 40 of 50 children. Results of selective
visceral arteriography suggested the presence of PAN in
96% of patients. Treatment included cyclophosphamide
and corticosteroids (83%), plasma exchange (9%), and
biologic agents (after 2002; 13%). The relapse rate was
35%, and the mortality rate was 4%. Severe GI involve-
ment was associated with increased risk of relapse (P 
0.031), while longer time to induce remission (P 
0.022) and increased cumulative dose of cyclo-
phosphamide (P  0.005) were associated with lower
relapse risk.
Conclusion. Childhood PAN is a severe inflam-
matory disease of insidious onset and variable clinical
presentation. Relapses occurred more frequently in
those with severe GI involvement. A higher cumulative
dose of cyclophosphamide was associated with a lower
risk of relapse.
Polyarteritis nodosa (PAN) was first described by
Kussmaul and Maier in 1866 (1). The original and
subsequent descriptions identified the pathologic fea-
tures of necrotizing arteritis with nodules along the walls
of medium and small muscular arteries, affecting multi-
ple organ systems throughout the body (2). Despite
some overlap with smaller vessel disease, PAN is a
distinct entity and has an estimated annual incidence of
2.0–9.0/million in adults (3). The onset of the disease is
typically between the ages of 25 and 50 years, but despite
the lack of good epidemiologic data, it is becoming
increasingly apparent that PAN occurs rather more
frequently during childhood than the literature might
suggest (2,4–6). Notably, the disease varies in its presen-
tation from a relatively benign cutaneous form, which
may resolve without treatment, to a severe systemic form
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(2,4–6). The etiology of PAN remains unclear, and it is
likely that environmental triggers and host susceptibility
play a key role (2).
System involvement in PAN varies, but the skin,
the musculoskeletal system, the kidneys, and the gastro-
intestinal (GI) tract are most prominently affected, with
cardiac, neurologic, and respiratory manifestations oc-
curring less frequently (2,6,7). The characteristic histo-
pathologic changes of PAN are fibrinoid necrosis of the
walls of medium or small arteries, with a marked inflam-
matory response within or surrounding the vessel wall
(2). The most valuable investigative procedure for the
disease is selective visceral angiography (2,8). Arterio-
graphic findings include aneurysms, segmental narrow-
ing, and variations in the caliber of arteries, together
with pruning of the peripheral vascular tree (8). Since
many of the presenting features of PAN are nonspecific
and mimic infectious or other, more common chronic
inflammatory diseases of childhood, there is often con-
siderable delay in diagnosis and a consequent delay in
initiation of treatment, resulting in irreversible end-
organ damage or death (2,4–6).
Documentation of large pediatric series of PAN
is limited (9–11). The largest multicenter series was
reported by Ozen et al (6) and described 110 children.
This included children with either systemic (63 patients)
or the milder cutaneous (33 patients) PAN, the latter
generally having a more benign course (4,6,7,12), while
the remaining children in that study had PAN associated
with hepatitis B and microscopic polyangiitis. These
previously published reports do not provide any basis for
evaluating the prognostic significance of presenting signs
and therapeutic approaches in the more severe systemic
form of PAN. In addition, long-term outcomes with
emphasis on disease and on treatment-related morbidity
and mortality have not yet been explored in childhood
PAN.
The aims of this study were to describe the
presenting clinical, histopathologic, and arteriographic
findings in children with systemic childhood PAN who
presented to Great Ormond Street Hospital for Chil-
dren NHS Foundation Trust, to describe the treatment
given, to define the factors present at the time of diagno-
sis that were predictive of relapse, and to describe other
longer-term complications of PAN and its treatment.
PATIENTS AND METHODS
Study population. Patients with a clinical diagnosis of
PAN who were seen at the Great Ormond Street for Children
NHS Foundation Trust between 1980 and 2012 and had been
monitored for at least 12 months were identified from clinical
and radiologic databases. Search terms used to look through
the clinical database included polyarteritis nodosa, vasculitis,
and PAN. Case notes were reviewed retrospectively, and
patients fulfilling the European League Against Rheumatism
(EULAR)/Paediatric Rheumatology European Society
(PRES)/Paediatric Rheumatology International Trials Organi-
sation (PRINTO) classification criteria for childhood PAN
were included in the study (13,14). The classification criteria
for childhood PAN are either histopathologic evidence of
necrotizing vasculitis in medium or small arteries or angio-
graphic abnormality (aneurysm, stenosis, or occlusion) as a
mandatory criterion plus 1 of the following 5 features: skin
involvement, myalgia or muscle tenderness, hypertension, peri-
pheral neuropathy, and renal involvement (13). Patients with
cutaneous PAN were excluded. Ethical approval was given by
the Institute of Child Health/Great Ormond Street Research
Ethics Committee for a retrospective review of case notes.
The demographic, clinical, and laboratory characteris-
tics recorded at the time of diagnosis were sex, age, ethnicity
(established via the information provided by patients or their
parents to register with the hospital), organ involvement, the
Paediatric Vasculitis Activity Score (PVAS) (15), the erythro-
cyte sedimentation rate (ESR), the serum C-reactive protein
(CRP) level, platelet count, presence of proteinuria and/or
hematuria, antineutrophil cytoplasmic antibody (ANCA) pos-
itivity (perinuclear or cytoplasmic), and histopathologic and
arteriographic findings. The full glossary of terms used in the
PVAS, as well as all variables of organ involvement assessed,
have been published elsewhere (15). The glomerular filtration
rate (GFR) was calculated retrospectively, based on the
plasma creatinine concentration, using the Schwartz formula
(16).
The time from diagnosis to first remission, the number
of relapses, and the relapse symptoms were also recorded. In
the case of deaths, information about the cause of the death
and the contributing factors were documented. We reviewed
the clinical charts for any clinical or laboratory signs of
remission or relapse at every visit in order to record a global
clinical evaluation in the database. Remission was defined as
the absence of any clinical signs/symptoms of active vasculitis,
as supported by laboratory evidence of normal CRP and ESR
values and a PVAS of 0 of 63 (assigned retrospectively for
every clinic visit), for 2 evaluations at least 1 month apart and
with adherence to the prednisolone regimen. Relapse was
defined as the recurrence of clinical signs/symptoms or the
occurrence of new symptoms (PVAS 0) after an initial
sustained remission of 3 months’ duration, requiring the
resumption of immunosuppressive therapy or the reinstitution
of corticosteroids (dosage increased by 50% to 0.5 mg/kg/
day).
Disease- and treatment-related morbidities, including
infection and corticosteroid-related side effects, were also
determined when the data were available. Osteopenia was
identified if the Z score for bone density on dual x-ray
absorptiometry (DXA) was 2 SD below the mean for the
patient’s age. DXA scans were performed on all children who
had been receiving corticosteroids for 6 months and were
repeated annually if children remained on steroid treatment.
We compared the time to diagnosis, relapse rates, and deaths
between the first and second 16-year study periods.
Statistical analysis. Continuous variables are summa-
rized as the median and range except where indicated other-
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wise. Categorical variables are presented as percentages and
frequencies. To investigate the prognostic significance of each
demographic, clinical, and laboratory characteristic, we com-
puted the hazard ratio (HR) and 95% confidence intervals
(95% CIs) for relapse in the study population as a whole, using
Cox’s regression analysis. Each variable was entered into a
univariable analysis, and significant variables (P  0.1) were
then entered into a multivariable analysis. The proportional
hazards assumption necessary for valid implementation of this
model was assessed graphically after model fitting (17). For the
analysis in which the first relapse was the outcome, patients
were censored at the last followup or death. The proportion of
patients surviving free of relapse was calculated using the
Kaplan-Meier method and is presented graphically for the
whole cohort. Kaplan-Meier curves were also plotted to assess
between-group differences in relapse rates and were compared
using log rank tests. All statistical analyses were performed
using SPSS software, version 18.0. P values less than 0.05
(2-sided) were considered significant.
RESULTS
Demographic and clinical characteristics. Sixty-
nine children who fulfilled the classification criteria for
PAN were identified over a 32-year period from January
1980 to January 2012. Their mean age was 8.5 years
(range 0.9–15.8 years), and 55% of them were male. The
median duration of followup was 6 years (range 1.5–16
years). The majority of the patients were Caucasian
(81%), 2 were Afro-Caribbean, and 11 were Asian. The
median interval from onset of the first symptom to
diagnosis was 1.2 months (range 0–20 months). The time
to diagnosis was longer during the first 16 years of the
study (median 1.1 months [range 0.4–20 months]) as
compared to the second 16 years of the study period
(median 0.6 months [range 0–15 months]; P  0.04).
The median PVAS at presentation was 9 of 63 (range
4–24).
The diagnosis of vasculitis was based on a com-
bination of histopathologic evidence of necrotizing vas-
culitis in medium or small arteries and catheter digital
subtraction arteriography (showing aneurysm, stenoses,
and/or occlusion of a medium or small artery not due to
fibromuscular dysplasia or other noninflammatory
causes) in 43 of the 69 patients. In 22 of the 69 patients,
arteriography alone was suggestive of medium-sized
vessel vasculitis, and in 4 of the 69 patients, the diagnosis
was based on histologic findings (skin biopsy samples
revealed necrotizing vasculitis in medium-sized arteries),
without arteriographic data.
The presenting clinical features are summarized
in Table 1. Presenting features by organ system in the 69
study patients were as follows (descending order of
frequency): skin involvement in 61 (88%), fever in 60
(87%), myalgia in 57 (83%), arthralgia/arthritis in 52
(75%), fatigue in 43 (62%), weight loss in 44 (64%),
renal involvement in 13 (19%), hypertension in 11
(16%), severe GI involvement in 7 (10%), central ner-
vous system involvement in 7 (10%), and peripheral
neuropathy in 3 (4%). Additional categories and specific
features are listed in Table 1. Skin nodules (16 patients
Table 1. Presenting clinical features in the 69 children with polyar-
teritis nodosa*
Presenting features
No. (%) of
patients
(n  69)
Fever 60 (87)
Weight loss 5% of body weight 44 (64)
Fatigue 43 (62)
Myalgia or muscle tenderness 57 (83)
Arthralgia or arthritis 52 (75)
Skin involvement
Livedo reticularis (purplish reticular pattern, usually
irregularly distributed around subcutaneous fat
lobules, often more prominent with cooling)
34 (49)
Skin nodules (tender subcutaneous nodules) 16 (23)
Purpura 28 (41)
Superficial skin infarctions (involving skin and
superficial subcutaneous tissue) or other minor
ischemic changes (nailbed infarctions, splinter
hemorrhages, digital pulp necrosis)
3 (4)
Deep skin infarctions (involving deep subcutaneous
tissue and underlying structures); necrosis/
gangrene of digital phalanx or other peripheral
tissue (nose and ear tips)
3 (4)
Other skin vasculitis (e.g., subcutaneous edema, RP) 16 (23)
Hypertension (systolic/diastolic blood above 95th
percentile for height)
11 (16)
Renal involvement
Proteinuria (0.3 gm/24 hours or urinary albumin-
to-creatinine ratio 30 mmoles/mg in a spot
morning sample)
13 (19)
Hematuria (5 RBCs/hpf or RBC casts in the
urinary sediment or 2 on dipstick)
7 (10)
Impaired renal function (10% increase in urinary
creatinine or 25% decrease in creatinine
clearance [GFR])
10 (15)
Neurologic involvement
Motor mononeuritis multiplex 3 (4)
Sensory peripheral neuropathy 3 (4)
Meningitis/encephalitis 3 (4)
Cranial nerve palsy 4 (6)
Stroke 7 (10)
Testicular swelling/pain 4 (6)
Gastrointestinal involvement
Abdominal pain 28 (41)
Peritonitis 3 (4)
Blood in the stool or bloody diarrhea 7 (10)
Bowel ischemia/perforation 3 (4)
Cardiac involvement
Valvular heart disease 2 (3)
Pericarditis 1 (1)
Pulmonary involvement
Pleural effusion 1 (1)
Infiltrate 1 (1)
* RP  Raynaud’s phenomenon; RBCs  red blood cells; hpf 
high-power field; GFR  glomerular filtration rate.
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[23%]) and purpura (28 patients [41%]) were frequent,
with livedo reticularis (34 patients [49%]) being the most
common skin manifestation of the disease in the 69
study patients. Arthralgia that was not accompanied by
joint deformity was present in 52 patients (75%). Myal-
gia was a prevalent clinical symptom reported in 57 cases
(83%).
Abdominal pain was present in 28 patients
(41%): 21 of these 28 patients had transient abdominal
pain, which regressed spontaneously or in response to
corticosteroid therapy and required no further investi-
gation. The remaining 7 patients (10% of the study
group) had more serious gastroenterologic pathology. In
7 patients, gastrointestinal hemorrhage (melena or he-
matemesis) was present. A laparotomy was performed in
3 of these patients. The most severe episodes of abdom-
inal pain were due to peritonitis (3 patients), duodenal
ulcer (1 patient), intestinal infarction (1 patient), and
large bowel perforation (3 patients).
The urinary albumin-to-creatinine ratio was 30
mmoles/mg in 13 patients and was accompanied by
hematuria (5 red blood cells/high-power field or the
presence of red blood cell casts) in 7 patients. Significant
renal involvement, as manifested by urinary creatinine
levels elevated above the 95th percentile for age, was
found in 10 of the 69 patients (15%), with a median
GFR of 60 ml/minute/1.73 m2 (range 41–80) in these 10
patients. Dialysis was necessary in 3 of the 69 patients
(4%).
Peripheral neuropathy and mononeuritis multi-
plex were observed in some patients (3 patients each
[4%]). Cranial nerve palsies involving cranial nerves III,
IV, VI, and VII occurred in 4 patients. Strokes, which
were defined as cerebrovascular accidents resulting in
focal neurologic deficits, were documented in 7 patients
and were associated with evidence of cortical or subcor-
tical infarction.
All patients had elevated levels of acute-phase
reactants at diagnosis, with a median ESR of 64 mm/
hour (range 40–140), a median CRP of 56 mg/liter
(range 35–120), and a median platelet count of 540 
109/liter (range 250–750  109/liter). Testing for ANCA
antibodies yielded positive results in 2 of the 69 patients
(on immunofluorescence not confirmed on enzyme-
linked immunosorbent assay, since that was not available
at time of testing).
Histopathologic findings. Fifty-five patients un-
derwent biopsy (10 renal and 60 nonrenal biopsies).
Histopathologic assessment of the skin showed necrotiz-
ing vasculitis of small to medium-sized vessels was
observed in 80% of the biopsy samples (40 of 50
biopsies), and 2 samples additionally revealed septal
panniculitis. Nongranulomatous necrotizing vasculitis
was found in 7 of the 10 biopsy samples from the GI
tract. These intestinal biopsies were obtained via
esophagogastroduodenoscopy, which was requested in
view of the patients’ reports of GI symptoms. Of the 10
renal biopsies performed, 2 were normal. Of the 8
abnormal renal biopsy samples, 2 showed focal segmen-
tal glomerulonephritis, 2 showed 10% crescent forma-
tion, and the remaining 4 showed membranoprolifera-
tive glomerulonephritis with necrotizing vasculitis, which
was considered diagnostic of PAN. Fibrin deposition
with vessel occlusion was noted in 3 of the 8 abnormal
renal biopsy samples.
Catheter digital subtraction arteriography and
other vascular imaging. Arteriography revealed aneu-
rysm formation or other changes consistent with vascu-
litis (arterial cutoff, arterial tapering, focal stenosis,
beading of arteries or other caliber variations, pruning of
the peripheral renal arterial tree, or perfusion defects on
nephrography) in various mid-sized arteries in 94% of
the patients (65 of 69 patients) (Table 2). Arteriographic
changes were present in the renal, hepatic, mesenteric,
and cerebral arteries in 62 of 66, 45 of 66, 22 of 66, and
7 of 35 patients, respectively. Five patients had normal
findings on magnetic resonance angiography, while dig-
ital subtraction arteriography studies in the same 5
patients revealed the presence of arteriographic changes
consistent with PAN. Echocardiography revealed in-
volvement of the coronary arteries in 3 patients (4%).
Treatment. The treatments received by the study
patients are summarized in Table 3. All patients
achieved remission, with a median of 2 months (range
1–24 months) from diagnosis to remission (defined as
PVAS of 0 of 63 plus normalization of acute-phase
reactant levels).
Induction therapy. Fifty-seven patients (83%) re-
ceived induction therapy with a combination of cortico-
steroids and cyclophosphamide. Of these 57 patients, 30
Table 2. Summary of the findings of catheter angiography in the 69
children with polyarteritis nodosa*
Arteriographic changes
No. (%)
of studies
Aneurysms 32 (46)
Arterial cutoff 18 (26)
Arterial tapering stenosis 22 (32)
Beading of arteries or other caliber variations 54 (78)
Pruning of peripheral renal arterial tree 24 (35)
Perfusion defects on nephrography 20 (29)
* A total of 66 catheter angiographic studies showed changes support-
ing a diagnosis of polyarteritis nodosa in this cohort. See ref. 8 for a
detailed description of each of the arteriographic signs.
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received oral cyclophosphamide (first-line therapy from
1980 to 2002), 24 received intravenous (IV) cyclo-
phosphamide (first-line therapy from 2002 onward), and
3 initially received IV cyclophosphamide and were then
switched to oral cyclophosphamide early in the disease
course. In general, a course of pulse cyclophosphamide
consisted of monthly doses of IV cyclophosphamide at
500–750 mg/m2 (maximum 1.2 gm) for a total of 6 doses,
which was administered to 17 patients (regimen used
from 1980 to 2006). For the remaining 10 patients given
pulse cyclophosphamide, the regimen consisted of fort-
nightly doses of IV cyclophosphamide at 500–750 mg/m2
for a total of 3 doses, followed by monthly treatments for
another 2–4 doses (regimen used from 2006 onwards).
The median cumulative dose of IV cyclophosphamide
received was 110 mg/kg (range 90–120). A course of oral
cyclophosphamide (1–2 mg/kg/day) was for 2–4 months
(median cumulative dose 240 mg/kg [range 120–745]).
All 69 patients received high-dose IV pulse cortico-
steroids at a dosage of 30 mg/kg/day for 3 consecutive
days, followed by a tapering dose of oral steroids over
12–18 months. Eight patients (12%) received a combi-
nation of corticosteroids and azathioprine (2 mg/kg/day)
for induction of remission, and 4 patients (6%) were
treated with corticosteroids alone, based on the clini-
cian’s discretion.
Maintenance and adjunctive therapies. Patients
achieving remission were maintained on a regimen of
either azathioprine (2 mg/kg/day) or mycophenolate
mofetil at a dosage of 600 mg/m2 twice a day for 18–48
months. Sixty-three patients (91%) received aspirin or
dipyridamole as an antithrombotic agent. Three patients
(4%) received intravenous iloprost infusion for critical
digital ischemia. Fourteen patients (20%) received
trimethoprim/sulfamethoxazole, generally as Pneumo-
cystis jiroveci pneumonia prophylaxis. Of note, prophy-
laxis with trimethoprim/sulfamethoxazole is currently
used in all patients with PAN but was inconsistently used
at our institution over the 32-year study period. Penicil-
lin prophylaxis was added in 21 children (30%) in whom
a streptococcal infection was believed to be the trigger of
their disease presentation. Other adjunctive modalities
used to induce remission and/or to treat recalcitrant
vasculitis included plasma exchange (6 patients, 5 with
glomerulonephritis and 1 with cerebral vasculitis; 2
volume exchanges per day over 7 cycles in all 6 patients),
methotrexate (6 patients; 10–15 mg/m2/week orally or
subcutaneously), infliximab (5 patients; 6 mg/kg IV at 0,
2, 4 weeks and then every 6 weeks thereafter), cyclo-
sporine (3 patients; 3–5 mg/kg orally twice a day), and
rituximab (3 patients; 2 IV doses of 750 mg/m2 given 14
days apart, with IV cyclophosphamide at 375 mg/m2).
Thirty-four (49%) children discontinued all treatment at
a median of 36 months (range 25–60 months) from their
initial diagnosis.
Relapse. A total of 24 patients (35%) experi-
enced a relapse of their disease at a median of 12 months
(range 7–48 months) and had a median of 2 episodes of
relapse (range 1–4 episodes) (Figure 1A). Of these 24
patients, 22 were receiving maintenance therapy, and 2
had stopped therapy a median of 4 months (range 3–6
months) previously. Overall, in the univariable analysis,
GI involvement (blood in the stool or bloody diarrhea,
and/or peritonitis, and/or bowel ischemia) was associ-
ated with an increased risk of relapse (HR 3.980 [95%
CI 1.142–13.868], P 0.031). A longer time to achieving
remission was associated with a lower risk of relapse
(HR 0.369 [95% CI 0.157–0.865], P  0.022) (Table 4),
as was an increased cumulative cyclophosphamide dose
(HR 0.995 [95% CI 0.795–0.995], P  0.005). These
parameters remained significantly associated with re-
lapse risk in the multivariable model (increased risk for
GI involvement HR 3.820 [95% CI 1.201–12.548], P 
0.035; lower risk with increased time to remission HR
0.340 [95% CI 0.160–0.986], P  0.03; and lower risk
with increased cumulative cyclophosphamide HR 0.895
[95% CI 0.795–0.998], P  0.003). All patients with
severe GI involvement experienced a relapse following
the onset of GI manifestations. Male sex, age 5 years,
PVAS at diagnosis, myalgia/arthralgia, skin, renal, and
neurologic involvement, ESR 100 mm/hour, CRP
100 mg/liter, and platelet count were not significant on
univariable analysis (Table 4). Relapse rates for all
patients with PAN according to severe GI disease status
Table 3. Treatment in the 69 children with polyarteritis nodosa
Treatment
No. (%)
of patients
Corticosteroids 69 (100)
Cyclophosphamide
Oral 33 (48)
Intravenous 27 (39)
Azathioprine 54 (78)
Mycophenolate mofetil 9 (13)
Methotrexate 6 (9)
Infliximab 5 (7)
Rituximab 3 (4)
Cyclosporine 3 (4)
Colchicine 2 (3)
Intravenous immunoglobulin 2 (3)
Etanercept 1 (1)
Hydroxychloroquine 1 (1)
Mesalamine 1 (1)
Plasma exchange 6 (9)
Aspirin 39 (57)
Dipyridamole 24 (35)
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are shown in Figure 1B. There was no significant differ-
ence in the relapse rate between the first 16 years of the
study period and the second 16 years of the study period
(P  0.671).
Adverse events and deaths. Significant cortico-
steroid-induced side effects included Cushing’s syn-
drome (22 of 69 patients [32%]) and osteopenia (18 of
69 patients [26%]). One child developed azoospermia
secondary to testicular vasculitis. A total of 19 infections
occurred in 17 patients. Two patients contracted shin-
gles, 1 patient (4 years old with a background of duplex
kidney) developed pyelonephritis requiring intravenous
antibiotics and hospitalization, another patient (8 years
old) developed cerebral abscesses complicating her
acute presentation with bowel perforation due to her
active PAN. Other infections in the 69 patients included
paronychia in 2 patients, staphylococcal cellulitis in 1,
chickenpox in 4, dental abscess in 1, pertussis infection
in 1, urinary tract infections in 2, aspergillosis in 1,
Epstein-Barr virus reactivation in 1, cytomegalovirus
Figure 1. A, Relapse-free survival in 69 children with polyarteritis nodosa (PAN) over a 3-year period of followup. B, Relapse-free survival in 69
children with PAN over a 1-year period, according to the presence (red line) or absence (black line) of severe gastrointestinal (GI) disease. The rates
differed significantly between patients with severe GI disease (blood in stools or bloody diarrhea, and/or peritonitis, and/or bowel ischemia) at any
stage and those without severe GI disease (2-sided P  0.0006, by log rank test).
Table 4. Association between the clinical and laboratory findings
and the risk of relapse in 66 children with polyarteritis nodosa*
Hazard ratio
(95% CI) P
Male sex 1.531 (0.443–5.285) 0.501
Age 5 years 1.012 (0.909–1.126) 0.828
PVAS at diagnosis 1.020 (0.939–1.108) 0.636
Myalgia/arthralgia 0.869 (0.358–2.112) 0.757
Skin involvement 1.345 (0.540–3.351) 0.524
Renal involvement 1.602 (0.606–4.237) 0.342
Neurologic involvement 1.234 (0.408–3.735) 0.710
Severe GI involvement 3.980 (1.142–13.868) 0.031
ESR 100 mm/hour at diagnosis 1.537 (0.625–3.780) 0.349
CRP 100 mg/liter at diagnosis 1.601 (0.875–3.560) 0.412
Time to remission, months 0.369 (0.157–0.865) 0.022
Cumulative CYC dose, mg/kg 0.895 (0.792–0.998) 0.005
* Three of the 69 children died during the study period. Hazard ratios
and 95% confidence intervals (95% CIs) were determined by Cox
regression analysis. Severe gastrointestinal (GI) involvement was
defined as blood in the stool or bloody diarrhea, and/or peritonitis,
and/or bowel ischemia. Time to remission was defined as the time from
diagnosis to the time of remission (defined as a Paediatric Vasculitis
Activity Score [PVAS] of 0 of 63). P values less than 0.05 (2-sided)
were considered significant. ESR  erythrocyte sedimentation rate;
CRP  C-reactive protein; CYC  cyclophosphamide.
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infection in 1, and mycobacterial infection in 1 patient.
No hepatitis B infections were noted.
A total of 3 deaths occurred during the observa-
tion period (all in the first 16 years of the study period),
yielding a mortality rate of 4%. These 3 children died
after a median followup of 3 weeks (range 4–8 weeks)
and without ever achieving remission. One of the chil-
dren was 2 years old and had presented with acute renal
failure, livedo reticularis, arthralgia, myalgia, fever,
weight loss, and left-sided hemiparesis. Arteriography
showed small aneurysms in the renal and cerebral
circulation. She received therapy with corticosteroids,
IV cyclophosphamide, and plasma exchange, but died of
staphylococcal septicemia 3 weeks after initial presenta-
tion. The second child was 12 years old and had pre-
sented with weight loss, fever, livedo reticularis, myalgia,
and hypertension. Arteriography demonstrated small
aneurysms in the hepatic and intrarenal arteries. He was
treated with high doses of IV corticosteroids and IV
cyclophosphamide but died of gram-negative bacterial
septicemia 5 weeks following initial presentation. The
third child was 12.5 years old and had presented with
fever, myalgia, and arthritis. Arteriography revealed
multiple small aneurysms in the intrarenal renal and
hepatic arteries. He died of invasive aspergillosis and
atypical mycobacterial infection 8 weeks following hos-
pital admission. There was no documented infertility or
malignancy during pediatric followup.
DISCUSSION
Our retrospective study describes the largest
single-center cohort of pediatric patients with systemic
PAN and adds to the available data from previously
reported series. The clinical presentation was varied and
broad, reflecting the multisystemic nature of childhood
PAN. Tissue biopsy and visceral digital subtraction
arteriography were important diagnostic tools in our
patients. First-line treatment for induction of remission
was a combination of high-dose corticosteroids and
cyclophosphamide; plasma exchange and biologic agents
were used for refractory cases. Azathioprine combined
with low-dose corticosteroids was the most common
maintenance therapy. The main clinical predictor of
relapse was severe GI involvement. A longer time to
achieving remission and an increased cumulative cyclo-
phosphamide dose were associated with reduced risk of
relapse. The mortality rate was 4%, which was an
improvement over the 10% mortality rate for systemic
PAN last reported at our institution in 2002 (18),
possibly reflecting increased awareness of the disease,
leading to prompt referral and advances in available
therapies, particularly biologic agents (19), for recalci-
trant systemic vasculitis. Despite this, treatment failure
and disease- and therapy-related morbidity remain sig-
nificant concerns for systemic PAN.
Most of our patients presented with nonspecific
constitutional symptoms, such as fever, fatigue, weight
loss, and myalgia. The other major systems involved
were the skin (88%), the musculoskeletal system (75%),
and less frequently, the renal system (19%). However, a
significant percentage of patients had gastrointestinal
(10%) and neurologic involvement (10%) as well. Nota-
bly, 2 patients demonstrated both typical mid-size and
small artery involvement, manifesting aneurysms on
renal arteriography in addition to glomerulonephritis
confirmed on renal biopsy. This degree of polyangiitis
overlap has been well described in the primary systemic
vasculitides, and this highlights the limitations of the
current classification systems that are based on the size
of involved arteries (2,20).
The diagnosis of PAN was based on a combina-
tion of clinical criteria, characteristic histopathologic
changes, and the presence of arteriographic changes
compatible with medium-size vessel arteritis. Systemic
PAN often presents insidiously, which may partly explain
the delay in diagnosis (average of 1.2 months, consider-
ably longer in some cases). The classic arteriographic
finding of aneurysms of medium and small muscular
arteries predominantly affecting the renal and mesen-
teric arteries has been well documented and accepted as
largely diagnostic (although not pathognomonic) of
PAN (2,8,21). Well recognized but less emphasized are
the nonaneurysmal changes affecting the smaller order
vessels (8). It has been shown that children with PAN
manifest a spectrum of aneurysmal and nonaneurysmal
angiographic changes that affect the renal, hepatic, and
mesenteric vascular beds (8). Although larger aneurysms
can be detected with computed tomographic angio-
graphy or even ultrasound, in our experience, these are
uncommon in children, and such techniques cannot
currently identify the subtle arterial abnormalities that
are much more prevalent.
Induction therapy with oral and/or high-dose
pulse IV corticosteroids, cyclophosphamide, and anti-
platelet agents, followed by maintenance therapy with
low-dose prednisolone and a steroid-sparing agent (most
commonly azathioprine) was standard in our patients.
The case for this approach is based largely on clinical
trials in adults with PAN (22,23) or other forms of
systemic vasculitis, particularly the ANCA-associated
vasculitides (AAVs) (24), since there has never been a
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randomized controlled trial in PAN. More-invasive ther-
apies, such as plasma exchange, were reserved for those
in whom remission was not achieved with standard
therapy or those who presented with fulminant, acutely
life-threatening vasculitis. Successful treatment with bio-
logic agents, such as infliximab or rituximab, has been
previously reported in children with systemic vasculitis
unresponsive to conventional therapy or in cases where
there are concerns relating to high cumulative doses of
cyclophosphamide (19), and after 2002, biologic agents
were used in a minority of our patients (9% receiving
infliximab or etanercept and 4% receiving rituximab)
(19). Since 2005, treatment of systemic PAN at our
center has been standardized (16,25).
Notably, severe short-term complications, such as
infections and corticosteroid-induced side effects, were
observed, and these remain a concern for children with
PAN receiving standard therapy. Furthermore, late
complications associated with cyclophosphamide ther-
apy include malignancy and infertility (26,27), which are
particularly worrisome for children with many years of
life ahead of them. Although we did not detect these
complications in our retrospective review, this could be
because of the relatively short followup in our cohort
and the lack of systematic screening for infertility in
pediatric patients exposed to cyclophosphamide who
graduate to adult care. The importance of this is empha-
sized by a report of 8 children with AAV who were
monitored for 11–30 years: 4 were infertile, 2 had
skeletal complications, and 1 developed a malignancy
(28). These worrying data, albeit limited and related to
AAV, emphasize the need for long-term followup stud-
ies of children with systemic PAN and other systemic
vasculitides who survive into adulthood (29). Thus,
finding the most efficacious and least toxic therapeutic
regimen remains an important priority for systemic
PAN.
The relapse rate for systemic PAN in our series
was 35%, somewhat higher than the relapse rate of 8.9%
for systemic PAN previously reported in a retrospective
multicenter cohort (6). This could suggest a referral bias,
with more severe and relapsing cases being referred to
our hospital since it is a specialist pediatric vasculitis
center that accepts national and international referrals.
Our observed relapse rate, however, was lower than the
50% relapse rate widely reported for adults with granu-
lomatosis with polyangiitis (Wegener’s) (30). Childhood
PAN, therefore, appears to be a condition in which
permanent remission can be achieved (2,4,6). Relapses
do occur, but despite these, a real possibility of cure can
be anticipated (2,4,6).
The finding that severe GI disease was associated
with an increased risk of relapse of systemic PAN is a
novel observation. We have previously reported on a
series of children with systemic PAN presenting with
indeterminate intestinal inflammation, and highlighted
the diagnostic challenges and significant morbidity and
mortality associated with GI involvement (31). Similarly,
Guillevin et al have also demonstrated a poor outcome
(increased mortality) for adult patients with PAN and
intestinal disease (32). Of note however, the limited
number of patients and the retrospective nature of this
study did not allow us to explore in detail the factors
contributing to the association of GI disease with in-
creased relapse risk. Interestingly, longer time to achieve
remission was associated with reduced relapse risk. This
may have been due to higher cumulative cyclo-
phosphamide doses used in those patients as shown
herein and as also suggested by meta-analysis data from
adults with AAV (30). Furthermore, the use of multiple
sequential treatments (cyclophosphamide, plasmaphere-
sis, and biologic agents) to obtain disease control in
select cases may have resulted in a reduced relapse risk
in these children.
We report a mortality rate of 4%, which is lower
than that reported in previous series (11,18,33). We
speculate that this could be due to increased disease
awareness leading to prompt tertiary center referral,
and/or improved treatments including introduction of
biologic agents in 2002 for recalcitrant cases (7,18).
Our study is limited by all the confounding
factors associated with any retrospective case series. As
highlighted previously, there is a possibility that referral
bias resulted in us receiving the most severe cases of
systemic PAN. Additionally, we did not monitor our
patients into adulthood and, hence, cannot fully assess
long-term sequelae (including late relapses) of systemic
PAN and its treatment. Late morbidity, such as prema-
ture atherosclerosis, and the aforementioned concerns
regarding malignancy and infertility could occur many
years after the onset of systemic PAN. Notably, a
previous study in children with PAN demonstrated
increased pulse wave velocity (a measure of arterial
stiffness) and, hence, decreased arterial distensibility
that was amplified during acute inflammatory exacerba-
tions (34). Clinical trials in adults suggest that mycophe-
nolate mofetil could be a less toxic alternative to cyclo-
phosphamide, with comparable efficacy, in the
treatment of systemic lupus erythematosus (35). A mul-
ticenter, open-label, randomized controlled trial (RCT)
of mycophenolate mofetil versus cyclophosphamide for
the induction of remission of childhood PAN (the
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MYPAN trial) is thus currently being developed and is
the first RCT of treatment in systemic PAN.
In summary, we report the largest single-center
series of patients with childhood systemic PAN. Improv-
ing the safety of treatments while maintaining or im-
proving efficacy needs to be the focus for the future.
RCTs linked to prospective long-term followup studies
are now urgently needed in order to provide the cur-
rently lacking evidence base for the treatment of chil-
dren with PAN.
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Clinical Images: Vascular malformation as a cause of limp in a child
The patient, a 4-year-old boy, presented with recurrent episodes of right knee pain and swelling associated with an antalgic gait of
2 years’ duration. The episodes lasted for a few hours and as long as 2 days, without precipitating or relieving factors. Results of
physical examination performed when the patient was asymptomatic were normal. Specifically, muscle atrophy was not found;
however, a hemangioma over the upper lateral right thigh and buttock (left) was noted. Complete blood cell count, erythrocyte
sedimentation rate, C-reactive protein levels, and antinuclear antibodies were normal or negative. The D-dimer level was 5.4 g/ml
(normal 0.51). Magnetic resonance imaging (MRI) (STIR image) of the right thigh showed a large lobulated, multiseptated,
hyperintense soft tissue mass involving the quadriceps muscle, gluteus muscle, and suprapatellar joint space. There was no evidence
of hemarthrosis or knee joint arthropathy (middle). Heterogeneous enhancement following intravenous injection of gadolinium was
seen (right). These findings are compatible with a venous malformation. The patient had an excellent clinical response to
intralesional sclerotherapy. Venous malformation is a congenital low-flow vascular malformation, consisting primarily of dilated and
disorganized venous channels that communicate with normal veins. In the knee, it causes episodic hemarthroses, and recurrent
hemarthroses can cause chronic changes similar to hemophilia. Thrombosis of the veins also may occur, which can lead to acute pain.
Bluish cutaneous lesions of venous malformation or prominent superficial veins found on physical examination may provide a clue
to the diagnosis, and in large venous malformations, hypofibrinogenemia and elevation of D-dimer levels may result from continuous
formation of intralesional microthrombi (Tsai A, Chaudry G, Spencer S, Kasser JR, Alomari AI. Misdiagnosis of knee venous
malformation as juvenile idiopathic arthritis. J Pediatr Orthop 2011;31:683–90). MRI plays a pivotal role in identifying the lesion
(Dalmonte P, Granata C, Fulcheri E, Vercellino N, Gregorio S, Magnano G. Intra-articular venous malformations of the knee.
J Pediatr Orthop 2012;32:394–8). Therapy should be tailored to each patient, and treatment options include sclerotherapy or
synovectomy.
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